SEER-Medicare: Requirements of Investigators Following Receipt of the Data
Investigators who have received the SEER-Medicare data must abide by the policies established by NCI and the SEER
program. These include the following:
- Researchers must send a copy of any manuscript to the SEER-Medicare contact prior to submitting it to a
journal for review. Please indicate the principal investigator and the approved
project title when sending the manuscript. This review is to ensure the
confidentiality of patients and providers in SEER areas and that the manuscript
topic matches the approved project. The review is not intended for the purpose
of assessing the scientific merit of a manuscript. Researchers are not required
to submit copies of meeting abstracts, power point presentations or
dissertations for review. However, all presentations and abstracts using
SEER-Medicare data must comply with requirements about cell sizes, mapping and
protection of patients and providers as described on the SEER-Medicare DUA (RTF, 126 KB).
- NCI would appreciate the inclusion of the following acknowledgment in any publication or presentations using SEER-Medicare
"This study used the linked SEER-Medicare database. The interpretation and reporting of these data are the sole
responsibility of the authors. The authors acknowledge the efforts of the Applied Research Program, NCI; the Office
of Research, Development and Information, CMS; Information Management Services (IMS), Inc.; and the Surveillance,
Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER-Medicare database."
- Projects that use data from the California Cancer Registry or the Northern California
Cancer Registry are REQUIRED to include the following acknowledgement:
"The collection of the California cancer incidence data used in this study was
supported by the California Department of Public Health as part of the statewide cancer
reporting program mandated by California Health and Safety Code Section 103885; the
National Cancer Institute's Surveillance, Epidemiology and End Results Program under
contract N01-PC-35136 awarded to the Northern California Cancer Center, contract
N01-PC-35139 awarded to the University of Southern California, and contract N02-PC-15105
awarded to the Public Health Institute; and the Centers for Disease Control and
Prevention's National Program of Cancer Registries, under agreement #U55/CCR921930-02
awarded to the Public Health Institute. The ideas and opinions expressed herein are those
of the author(s) and endorsement by the State of California, Department of Public Health
the National Cancer Institute, and the Centers for Disease Control and Prevention or their
Contractors and Subcontractors is not intended nor should be inferred. The authors
acknowledge the efforts of the Applied Research Program, NCI; the Office of Research,
Development and Information, CMS; Information Management Services (IMS), Inc.; and the
Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the
creation of the SEER-Medicare database."
- If investigators want to use the data they have received for another project, they
must submit a new application and appropriate paperwork for review according to the instructions.
- Investigators moving / changing institutions must contact NCI prior to the move for
instructions on how to handle SEER-Medicare data.
- Investigators may not provide SEER-Medicare data to any other individual or
investigator. Contact NCI to discuss arrangements for ordering an extra copy of the
- Investigators may not link variables from the SEER-Medicare files to files other than
SEER-Medicare without the
written consent from the applicable SEER registries.
- Investigators may not publish or present findings in which the number of cases in a
cell is less than eleven. This policy is to eliminate the potential for
re-identification of persons with cancer.